All data are based on the daily closing price as of March 13, 2025
c

CJ Bioscience

311690.KQ
7.78 USD
0.01
+0.13%

Overview

Last close
7.78 usd
Market cap
101.52M usd
52 week high
13.34 usd
52 week low
6.21 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
36.1632
Price/Book Value
3.0252
Enterprise Value
77.99M usd
EV/Revenue
28.1589
EV/EBITDA
-6.5568

Key financials

Revenue TTM
2.77M usd
Gross Profit TTM
274068.27 usd
EBITDA TTM
-18.82M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
51.05M usd
Net debt
N/A usd

About

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company's platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson's diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics analysis portal for microbial research; EzBioCloud Pro, a next-generation analysis platform for infection diagnosis and microbial bioinformatics analysis; Gut Inside, a microbiome testing service; and TrueBac ID, a cloud-based service platform that can identify various bacterial species based on genomic data. The company was formerly known as ChunLab, Inc. and changed its name to CJ Bioscience, Inc. in December 2021. CJ Bioscience, Inc. was founded in 2009 and is based in Seoul, South Korea.
  • Symbol
    311690.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Seoul
  • Web site
    https://www.cjbioscience.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top